Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of pharmaceuticals for renal and vascular disease. Co.'s product candidate, vonapanitase, is a recombinant human elastase developed to improve vascular access outcomes in patients with chronic kidney disease undergoing or planning for hemodialysis. Co.'s other programs include the development of vonapanitase in brachiocephalic fistula creation, and arteriovenous grafts, a synthetic tube to connect a vein and an artery placed in a surgical procedure. In addition to vascular access indications, Co. is investigating vonapanitase as a treatment for patients with symptomatic peripheral artery disease. We show 23 historical shares outstanding datapoints in our PRTO shares outstanding history coverage, used to compute PRTO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PRTO market cap history over the course of time is important for investors
interested in comparing PRTO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PRTO versus a peer is one thing; comparing
PRTO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PRTO can fluctuate over the course of history.
With this page we aim to empower investors researching PRTO by allowing them to research the PRTO market cap history. |
Free PRTO Email Alerts:
Video: The Importance of Market Cap
